Homocysteine-induced impairment of insulin secretion from clonal pancreatic BRIN-BD11 beta-cells is not prevented by catalase.
OBJECTIVE
Although detrimental effects of homocysteine attributed to homocysteine auto-oxidation and generation of hydrogen peroxide (H2O2) have been reported in various cell types, such actions have not been considered in pancreatic beta-cells. This study investigates the acute effects of homocysteine on beta-cell integrity and regulation, in particular, the role of H2O2 generated by auto-oxidation.


METHODS
Assessment of beta-cell function was examined during acute 20- or 40-minute incubations with homocysteine using clonal BRIN-BD11 beta-cells.


RESULTS
Homocysteine (50-1000 micromol/L) inhibited basal and glucose-induced insulin secretion in a concentration-dependent manner. Insulinotropic responses to alanine, arginine, 2-ketoisocaproate, elevated Ca, tolbutamide, potassium chloride (KCl), forskolin, and phorbol 12-myristate 13-acetate were also significantly reduced by homocysteine. Likewise, preincubation with homocysteine caused a reduction in the insulinotropic responses to glucose and each of the secretagogues tested. Notably, excess catalase (100 microg/mL) in the buffer, although sufficient to remove homocysteine-derived H2O2, did not alleviate the detrimental effects of homocysteine.


CONCLUSIONS
Collectively, these data suggest that homocysteine impairs insulin secretory function by mechanisms independent of H2O2 generation. Although homocysteine may give rise to reactive oxygen species, these observations indicate detrimental non-oxidative pancreatic beta-cell actions of homocysteine.
Patterson
Steven
S
School of Biomedical Sciences, University of Ulster, Coleraine, UK. s.patterson@ulster.ac.uk
Flatt
Peter R
PR
McClenaghan
Neville H
NH
D000596:Amino Acids / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology*; D002460:Cell Line; D002999:Clone Cells; D005576:Colforsin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000494:pharmacology; D006710:Homocysteine / Q000494:pharmacology*; D006861:Hydrogen Peroxide / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D007651:Keto Acids / Q000378:metabolism / Q000494:pharmacology; D010084:Oxidation-Reduction; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology
D000596:Amino Acids; D002273:Carcinogens; D007004:Hypoglycemic Agents; D007328:Insulin; D007651:Keto Acids; D006710:Homocysteine; D005576:Colforsin; D011189:Potassium Chloride; D014044:Tolbutamide; D006861:Hydrogen Peroxide; D002374:Catalase; D005947:Glucose; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium